19. Kane LP, Lin J, Weiss A. It’s all Rel-ative: NF-kappaB and CD28 costimulation
of T-cell activation. Trends Immunol. 2002; 23: 413-420.
20. Boyman O, Sprent J. The role of interleukin-2 during homeostasis
and activation of the immune system. Nat Rev Immunol. 2012; 12: 180-
190.
21. Kozarsky KF, Call SM, Dower SK, Krieger M. Abnormal intracellular
sorting of O-linked carbohydrate-deficient interleukin-2 receptors. Mol
Cell Biol. 1988; 8: 3357-3363.
22. Stauber DJ, Debler EW, Horton PA, et al. Crystal structure of the IL-
2 signaling complex: paradigm for a heterotrimeric cytokine receptor.
Proc Natl Acad Sci U S A. 2006; 103: 2788-2793.
23. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current
overview. Cell. 1993; 73: 5-8.
24. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector
responses, tolerance, and immunotherapy. Immunity. 2013; 38: 13-25.
25. Shi H, Liu C, Tan H, et al. Hippo Kinases Mst1 and Mst2 Sense and
Amplify IL-2R-STAT5 Signaling in Regulatory T Cells to Establish Stable
Regulatory Activity. Immunity. 2018; 49: 899-914 e896.
26. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy
by selective stimulation of IL-2 receptors on lymphocytes
and endothelial cells. Proc Natl Acad Sci U S A. 2010; 107: 11906-11911.
27. Soerensen MM, Ros W, Rodriguez-Ruiz ME, et al. Safety, PK/PD, and
anti-tumor activity of RO6874281, an engineered variant of interleukin-
2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast
activation protein (FAP). Journal of Clinical Oncology. 2018; 36.
28. Melero I, Alvarez EC, Mau-Sorensen M, et al. Clinical activity, safety,
and PK/PD from a phase I study of RO6874281, a fibroblast activation
protein (FAP) targeted interleukin-2 variant (IL-2v). Annals of Oncology.
2018; 29.
29. Lopes JE, Losey HC, Dean RL, et al. Characterization of the pharmacodynamic
immune response to a novel immunotherapeutic agent,
ALKS 4230, in mice and non-human primates. Cancer Research. 2017;
77.
30. Pfannenstiel L, Lopes J, Losey H, et al. A novel, individualized
xenograft model of cancer immunotherapy and tumor growth inhibition
by ALKS 4230. Journal for Immunotherapy of Cancer. 2017; 5.
31. Vaishampayan U, Muzaffar J, Velcheti V, et al. ALKS 4230, an engineered
IL-2 fusion protein, in monotherapy dose-escalation and combination
therapy with pembrolizumab in patients with solid tumors:
ARTISTRY-1 trial. Journal for Immunotherapy of Cancer. 2019; 7.
32. Vaishampayan UN, Fishman MN, Cho DC, et al. Intravenous administration
of ALKS 4230 as monotherapy and in combination with
pembrolizumab in a phase I study of patients with advanced solid tumors.
Journal of Clinical Oncology. 2019; 37.
33. Powderly J, Carthon B, Ernstoff M, et al. ARTISTRY-2: a phase 1/2
study of subcutaneously administrated ALKS 4230 as monotherapy and
in combination with pembrolizumab in patients with advanced solid
tumors. Journal for Immunotherapy of Cancer. 2019; 7.
34. Arenas-Ramirez N, Zou C, Popp S et al. Improved cancer immunotherapy
by a CD25-mimobody conferring selectivity to human
interleukin-2. Sci Transl Med. 2016; 8: 367ra166.
35. Charych D, Khalili S, Dixit V et al. Modeling the receptor pharmacology,
pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically
controlled interleukin-2 (IL2) receptor agonist for cancer
immunotherapy. PLoS One. 2017; 12: e0179431.
36. Charych DH, Hoch U, Langowski JL et al. NKTR-214, an Engineered
Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure,
and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res 2016;
22: 680-690.
37. Bentebibel SE, Hurwitz ME, Bernatchez C et al. A First-in-Human
Study and Biomarker Analysis of NKTR-214, a Novel IL2Rbetagamma-
Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Cancer Discov 2019; 9: 711-721.
38. Siefker-Radtke AO, Fishman MN, Balar AV et al. NKTR-214+nivolumab
in first-line advanced/metastatic urothelial carcinoma (mUC):
Updated results from PIVOT-02. Journal of Clinical Oncology 2019; 37.
KCJ